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Abstract
Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast
cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2
mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers
display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).
Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis,
contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the
Surveillance, Epidemiology, and End Results (SEER) database.
Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared
with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for
trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence
interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of
grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also
presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12).
Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display
distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC
phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade).
These findings could lead to the development of gender-specific risk prediction models and guide clinical
strategies appropriate for MBC management.
Keywords: Male breast cancer, BRCA1/2, Pathology, Histologic grade, Genotype–phenotype correlations
Background
Male breast cancer (MBC) is a rare disease. It accounts
for less than 1 % of all breast cancers and less than 1 %
of all cancers in men. The annual incidence is estimated
at about 1 per 100,000 men worldwide [1], and lifetime
risk is less than 1 in 1000. Incidence rates for MBC in-
crease linearly and steadily with age, with the mean age
at diagnosis being between 60 and 70 years [2]. Family
history of breast cancer is an important risk factor for
developing MBC, suggesting the importance of genetic
factors in MBC susceptibility [3, 4]. Mutations in the
two major high-penetrance breast cancer genes, BRCA1
(breast cancer 1, early onset gene) and predominantly
BRCA2 (breast cancer 2, early onset gene), account for
approximately 10 % of MBCs outside populations with
BRCA founder mutations [5]. The lifetime risk of develop-
ing MBC has been estimated to be in the range of 1–5 %
for BRCA1 and 5–10 % for BRCA2 mutation carriers, com-
pared with a risk of 0.1 % in the general population [6–9].
MBC is recognised as being a hormone-dependent
malignancy, and it is widely accepted as an oestrogen-
driven disease, specifically related to hyperestrogenism
[10]. In the general population, MBC is similar to late-
onset, post-menopausal, oestrogen receptor–/progesterone
receptor–positive (ER+/PR+) female breast cancer (FBC).
However, compared with FBC, MBC has been reported to
occur later in life, present at a higher stage and display
lower histologic grade, with a higher proportion of ER+ and
PR+ tumours [11].
There is increasing evidence suggesting that MBC may
be a group of molecularly and clinically heterogeneous
malignancies which differ from those seen in women
[12]. It is well known that breast cancer in women is a
heterogeneous disease. Breast cancers arising in female
BRCA1 mutation carriers display characteristic pathologic
features, including distinct morphology (i.e., carcinomas
with medullary features) and a triple-negative phenotype
[i.e., ER−, PR−, human epidermal growth factor receptor
2–negative (HER2−)] in the majority. In contrast, BRCA2
breast tumours are a more heterogeneous group, being
broadly similar to non-BRCA–associated breast tumours,
which more closely resemble post-menopausal FBCs,
although with a tendency to be of high grade and
HER2− [13].
Current knowledge of the pathologic characteristics
of breast cancers arising in male BRCA1/2 mutation
carriers is limited, owing to the small number of carriers
included in individual studies [14–17]. In a study includ-
ing 50 male BRCA1/2 mutation carriers, it was suggested
that BRCA2 MBCs may represent a subgroup of tumours
with a peculiar phenotype not identified in FBC and
characterised by an aggressive biological behaviour
[16]. Furthermore, in a study including 28 male BRCA1/2
mutation carriers, a possible BRCA2 phenotype charac-
terised by micropapillary histology was suggested [17].
In other, smaller studies, BRCA2 MBCs were associated
with younger age at diagnosis and positive lymph node
status [14, 15].
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In this study, we report pathology data characteristics
of 419 BRCA1/2 MBCs derived from the Consortium of
Investigators of Modifiers of BRCA1/2 (CIMBA), who
conducted the largest study of its kind to date. The main
objective of our study was to characterise the pathologic
features of BRCA1/2 MBCs and contrast those with the
characteristics of BRCA1/2 FBCs, as well as with MBCs
in the general population.
Methods
CIMBA study participants
CIMBA collects data on male and female BRCA1 or
BRCA2 pathogenic mutation carriers older than 18
years of age, with the majority recruited through cancer
genetics clinics [18]. CIMBA data were submitted by 55
study groups in 24 countries based in Europe, North
America and Australia. Pathology data from MBC cases
for the present analysis were collected by 35 study groups
(Additional file 1). Key variables collected for all CIMBA
patients include year of birth, age at cancer diagnosis
(breast, ovarian or prostate cancers), age at last observation,
family membership, race and/or ethnicity and information
on applicable prophylactic surgeries. This work was re-
stricted to male and female mutation carriers who had been
diagnosed with breast cancer and were of self-reported
European ancestry. The number of male mutation carriers
of non-European ancestry (2 BRCA1 and 20 BRCA2) was
too small to allow a meaningful analysis. These subjects
were excluded from the analysis.
A signed informed consent form was obtained from
study participants. All participating studies were approved
by local ethical review committees (Additional file 2).
Tumour pathology data
MBC pathology data were obtained from a range of
sources, namely medical, pathology or tumour registry
records and immunohistochemical staining and/or scoring
of tissue microarrays (TMAs) (Additional file 3). The data
included information on ER, PR and HER2 status;
morphological subtype; lymph node involvement; TNM
(tumour, node, metastasis) staging; and histologic grade.
For ER, PR and HER2, status was classified as negative or
positive. The vast majority of centres employed a cut-off
of either ≥10 % or ≥1 % of tumour nuclei staining positive
to define ER/PR receptor positivity, which was not
centrally reclassified, owing to the low proportion of
records with supporting staining data (Additional file 3).
HER2 status was determined using immunohistochemistry
(IHC) to detect strong complete membrane staining (with
3+ considered positive) with in situ hybridisation to detect
HER2 gene amplification in equivocal cases. Consistency
checks were performed to validate receptor data against
supplementary scoring information when provided. Cen-
tral pathology review was not performed.
Each carcinoma was assigned to a morphologic sub-
group (ductal, lobular, medullary, other), which was con-
firmed using the World Health Organisation International
Classification of Diseases 0 code for the classification of
tumour type when present. Lymph node status, along with
the number of nodes showing metastatic carcinoma, was
provided when available. Staging data were based on the
AJCC Cancer Staging Manual, Sixth Edition [19], with
data provided on overall stage and its major attributes
(primary tumour size, regional lymph node involvement
and presence of distant metastasis). Histologic grade was
determined by local pathologists using modifications of
the Scarff-Bloom-Richardson histological grading system
as grade 1, 2 or 3. Pathology data for FBCs included in the
study are described in detail elsewhere [13].
SEER data
We obtained MBC pathology data from the SEER 18
Registries Database for cases diagnosed from 1973 to 2011
[20]. For this study, we selected only male Caucasian cases
diagnosed with invasive breast cancer. For SEER cases,
pathology characteristics included age at diagnosis;
morphologic subgroup; tumour grade; lymph node status;
adjusted stage based on the AJCC Cancer Staging Manual,
Sixth Edition [19]; ER, PR and HER2 status. Tumour
grade was classified as grade 1 (well differentiated),
grade 2 (moderately differentiated) or grade 3 (poorly
differentiated).
SEER includes unselected MBCs, most of which are of
unknown BRCA1/2 mutation status. On the basis of
published data [3, 21, 22], about 10 % of MBC cases are
expected to be due to BRCA1 or BRCA2 mutations.
Statistical methods
Logistic regression was used to assess the association
between pathologic characteristics and male BRCA1/2
mutation carrier status, as well as to compare patho-
logic characteristics with data from female BRCA1/2
mutation carriers and from male breast tumours arising
in the general population using SEER data. In the logistic
regression analysis, each pathologic characteristic was
treated as the explanatory variable. The outcome variables
were BRCA mutation status (BRCA1/BRCA2), sex (fe-
male/male) and carrier status (general population/BRCA1
mutation carrier and general population/BRCA2 mutation
carrier), with the first term used as the reference group.
For assessment of continuous or ordered variables, such
as age at diagnosis, stage and grade, tests for trend were
also performed.
Analyses within CIMBA data were adjusted for age at
diagnosis and country of origin, whereas comparisons
between CIMBA and SEER data were adjusted only for
age at diagnosis. In addition, an adjustment for calendar
year of diagnosis was included in all analyses, based on
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the following groupings: up to 1990, 1991–2000 and after
2000. A robust variance approach was used to allow for
dependencies between related individuals. All analyses
were carried out using Stata v13 software (StataCorp,
College Station, TX, USA).
Results
Pathologic characteristics of MBC in BRCA1 and BRCA2
mutation carriers
Information was available for 419 MBC cases, including
375 BRCA2 and 44 BRCA1 mutation carriers (Additional
file 1). Median age at MBC diagnosis was 62 years [inter-
quartile range (IQR) 16] for BRCA2 mutation carriers and
62 years (IQR 18) for BRCA1 mutation carriers.
The analysis was restricted to carriers diagnosed with
invasive breast cancer (326 BRCA2 and 40 BRCA1)
(Additional file 4). The majority of tumours were invasive
ductal carcinoma in both BRCA2 (95.1 %) and BRCA1
(100 %) carriers. Among tumours with data on stage and
grade, the majority of BRCA2 mutation carriers presented
with stage 2 disease (47 %) and tumours of histologic
grade 3 (56.7 %), whereas the majority of BRCA1 mutation
carriers presented with stage 3–4 disease (42.9 %) and
histologic grade 3 tumours (69.2 %). Among tumours
with ER, PR and HER2 data, 96.7 % were ER+, 86.8 %
were PR+ and 83.4 % were HER2− in BRCA2 mutation
carriers, vs. 90.3 % ER+, 78.6 % PR+ and 89.5 % HER2− in
BRCA1 mutation carriers.
Age at diagnosis was inversely associated with grade in
BRCA2 mutation carriers (grade 1/2 vs. grade 3, P = 0.005),
with no evidence for differences in ER, PR and HER2 distri-
butions by age (test for differences P > 0.05 for all) (Fig. 1).
Furthermore, there was no evidence of association between
grade and ER or PR status (P values for trend = 0.50 and
0.78, respectively). For BRCA1 mutation carriers, no differ-
ences in age-specific proportions of tumours by grade or
ER, PR and HER2 status were observed, but their numbers
were small (data not shown).
When we compared the pathologic characteristics of
MBC in BRCA1 and BRCA2 mutation carriers, we ob-
served no statistically significant differences. However, tu-
mours in BRCA1 mutation carriers were more likely to
Fig. 1 Age-specific proportion of BRCA2 (breast cancer 2, early onset gene) male breast cancers according to pathologic characteristics. a Grade.
b Oestrogen receptor (ER) status. c Progesterone receptor (PR) status. d Human epidermal growth factor receptor 2 (HER2) status. Error bars
represent confidence intervals associated with each proportion
Silvestri et al. Breast Cancer Research  (2016) 18:15 Page 4 of 13
present with more advanced stage (42.9 % vs. 23.5 %, P for
trend = 0.11) and were more frequently ER− (9.7 % vs.
3.3 %, P = 0.17) and PR− (21.4 % vs. 13.2 %, P = 0.27) than
tumours in BRCA2 mutation carriers (Additional file 4).
Characterisation of BRCA2 MBCs: comparison with BRCA2
FBC and with MBC in the general population
We evaluated possible pathologic differences between in-
vasive breast cancers arising in male and female BRCA2
mutation carriers by comparing available data from female
mutation carriers with breast cancer in the CIMBA
dataset. Data from 3750 country-matched female BRCA2
mutation carriers diagnosed with invasive breast cancer
were included in this analysis (Table 1). The results re-
vealed that there were significantly fewer invasive lobular
carcinomas among male BRCA2 mutation carriers than
among female BRCA2 mutation carriers [odds ratio (OR)
0.14, 95 % confidence interval (CI) 0.05–0.43]. In addition,
Table 1 Pathology of invasive BRCA2 female and male breast tumours and ORs in predicting male BRCA2 mutation carrier status
Females Males Unadjusted OR (95 % CI) Adjusted ORa (95 % CI)
Number Percent Number Percent
Totalb 3750 326
Morphology
Ductal carcinoma 2693 83.6 253 95.1 Reference Reference
Lobular carcinoma 276 8.6 4 1.5 0.15 (0.06–0.41) 0.14 (0.05–0.43)
Medullary carcinoma 60 1.9 2 0.8 0.35 (0.09–1.46) 0.46 (0.10–2.11)
Other 193 6.0 7 2.6 0.39 (0.18–0.83) 0.54 (0.24–1.23)
TNM stage
0–1 560 40.2 44 29.5 Reference Reference
2 629 45.1 70 47.0 1.42 (0.95–2.10) 1.97 (1.20–3.23)
3–4 205 14.7 35 23.5 2.17 (1.37–3.44) 3.55 (1.96–6.44)
Histologic grade
Grade 1 149 5.9 8 3.5 Reference Reference
Grade 2 1057 41.7 92 39.8 1.62 (0.77–3.41) 1.88 (0.76–4.67)
Grade 3 1329 52.4 131 56.7 1.84 (0.88–3.83 2.66 (1.08–6.55)
Lymph node status
Negative 1398 52.4 123 50.2 Reference Reference
Positive 1270 47.6 122 49.8 1.09 (0.84–1.43) 1.55 (1.12–2.14)
ER status
Negative 650 22.7 8 3.3 Reference Reference
Positive 2211 77.3 236 96.7 8.67 (4.26–17.66) 10.59 (5.15–21.80)
PR status
Negative 892 35.0 30 13.2 Reference Reference
Positive 1654 65.0 198 86.8 3.56 (2.41–5.26) 5.04 (3.17–8.04)
HER2 status
Negative 1404 85.9 126 83.4 Reference Reference
Positive 230 14.1 25 16.6 1.21 (0.77–1.90) 1.22 (0.70–2.11)
Subtypes
ER+ and/or PR+, HER2− 1112 69.8 118 81.9 Reference Reference
ER+ and/or PR+, HER2+ 182 11.4 22 15.3 1.14 (0.70–1.84) 1.18 (0.65–2.13)
ER−, PR−, HER2+ 40 2.5 2 1.4 0.47 (0.11–1.98) 0.42 (0.09–1.98)
Triple-negative (ER−, PR−, HER2−) 260 16.3 2 1.4 0.07 (0.02–0.30) 0.05 (0.01–0.22)
ER+ and/or PR+, HER2− vs. others 0.51 (0.33–0.79) 0.42 (0.25–0.70)
BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio,
PR progesterone receptor, TNM tumour, node, metastasis
Significant results are indicated by boldface type
aAnalyses adjusted for country, age at diagnosis and calendar year of diagnosis
bSome data for each pathologic feature are not available
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compared with BRCA2 FBCs, BRCA2 MBCs were of sig-
nificantly higher stage (P for trend = 2.14 × 10−5) and
higher grade (P for trend = 0.005), presented more fre-
quently with lymph node involvement (OR 1.55, 95 % CI
1.12–2.14) and were more likely to be ER+ (OR 10.59, 95
% CI 5.15–21.80), PR+ (OR 5.04; 95 % CI 3.17–8.04) and
non–triple-negative (OR 0.05, 95 % CI 0.01–0.22). Associ-
ations with stage and nodal, ER and PR status remained
significant after adjustment for grade.
We then compared pathologic features of MBC arising
in BRCA2 mutation carriers with characteristics of MBC
in the general U.S. population as represented by SEER.
We extracted pathology data of 6351 men with invasive
breast cancer from the SEER 18 database. There were no
statistically significant differences in pathology charac-
teristics between MBCs arising in BRCA2 mutation car-
riers and those arising in the general population, with
the exception of grade and lymph node status (Table 2).
Table 2 Pathology of invasive MBCs in the general population from SEER and BRCA2 MBCs and ORs in predicting male BRCA2
mutation carrier status
SEER BRCA2 carriers Unadjusted OR (95 % CI) Adjusted ORa (95 % CI)
Number Percent Number Percent
Totalb 6351 326
Morphology
Ductal carcinoma 5265 86.2 253 95.1 Reference Reference
Lobular carcinoma 82 1.5 4 1.5 1.02 (0.37–2.79) 1.00 (0.36–2.74)
Medullary Carcinoma 16 0.3 2 0.8 2.60 (0.59–11.38) 2.34 (0.52–10.39)
TNM stage
0–1 1699 34.9 44 29.5 Reference Reference
2 1990 40.9 70 47.0 1.36 (0.93.–1.99) 1.37 (0.93–2.01)
3–4 1181 24.2 35 23.5 1.14 (0.73–1.77) 1.11 (0.72–1.73)
Histologic grade
Grade 1 632 12.9 8 3.5 Reference Reference
Grade 2 2432 49.7 92 39.8 2.99 (1.44–6.19) 2.98 (1.44–6.19)
Grade 3 1834 37.4 131 56.7 5.64 (2.75–11.60) 5.53 (2.69–11.39)
Lymph node status
Negative 2773 58.0 123 50.2 Reference Reference
Positive 2009 42.0 122 49.8 1.37 (1.05–1.78) 1.28 (0.98–1.67)
ER status
Negative 229 5.3 8 3.3 Reference Reference
Positive 4064 94.7 236 96.7 1.66 (0.81–3.41) 1.95 (0.93–4.06)
PR status
Negative 627 15.0 30 13.2 Reference Reference
Positive 3562 85.0 198 86.8 1.16 (0.79–1.72) 1.30 (0.88–1.92)
HER2 status
Negative 627 87.8 126 83.4 Reference Reference
Positive 87 12.2 25 16.6 1.43 (0.88–2.32) 1.30 (0.79–2.13)
Subtypes
ER+ and/or PR+, HER2− 608 87.5 118 81.9 Reference Reference
ER+ and/or PR+, HER2+ 80 11.5 22 15.3 1.42 (0.85–2.36) 1.28 (0.76–2.17)
ER−, PR−, HER2+ 7 1.0 2 1.4 1.47 (0.30–7.18) 1.09 (0.22–5.45)
Triple-negative (ER−, PR−, HER2−) 0 0.0 2 1.4 – –
ER+ and/or PR+, HER2− vs. others 1.54 (0.95–2.49) 1.38 (0.84–2.27)
BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio,
PR progesterone receptor, TNM tumour, node, metastasis
Significant results are indicated by boldface type
aAnalyses adjusted for age at diagnosis and calendar year of diagnosis
bSome data for each pathologic feature are not available
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Male BRCA2 mutation carriers more frequently had grades
2 and 3 tumours than grade 1 tumours, as compared with
MBC cases from the general population (grade 2 vs. grade
1 OR 2.98, 95 % CI 1.44–6.19; grade 3 vs. grade 1 OR 5.53,
95 % CI 2.69–11.39; P for trend = 4.52 × 10−12). Moreover,
BRCA2 mutation carriers presented more frequently with
lymph node involvement than MBC cases from the general
population, a difference that was not significant when
adjusted for age at diagnosis and/or grade.
Characterisation of BRCA1 MBCs: comparison with BRCA1
FBC and with MBC in the general population
A total of 5925 country-matched female BRCA1 muta-
tion carriers diagnosed with invasive breast cancer were
compared with our BRCA1 MBC series, which revealed
that MBCs were of significantly higher stage (stage 3–4 vs.
stage 1 OR 17.59, 95 % CI 3.47–89.03; P for trend = 0.001)
and presented more frequently with lymph node involve-
ment (OR 2.19, 95 % CI 1.03–4.65) than FBCs in BRCA1
mutation carriers (Additional file 5). The association with
stage remained significant after adjusting for ER and PR
status. Moreover, BRCA1 MBCs were more likely to be
ER+ (OR 20.22, 95 % CI 5.91–69.17), PR+ (OR 13.76, 95
% CI 5.31–35.67) and non–triple-negative (OR 0.03, 95 %
CI 0.00–0.25). The associations with ER and PR status
remained significant after adjustment for stage. There was
no statistically significant difference in the distribution of
histologic grade among male and female BRCA1 breast
cancers.
The comparison between MBCs arising in BRCA1 mu-
tation carriers with those of 6351 MBCs from the SEER
database showed no significant differences in pathologic
characteristics (Additional file 6). However, BRCA1 male
breast tumours trended toward higher grade compared
with those in the general population (P for trend = 0.003).
Discussion
To date, most of the available knowledge on MBC is
based on MBC arising in the general population, whose
BRCA1/2 mutation status is largely unknown. In this
study, we sought to determine whether MBC arising in
BRCA1 and BRCA2 mutation carriers displayed specific
pathologic characteristics. We used data on 419 MBCs with
BRCA1 and BRCA2 mutations from an international con-
sortium (CIMBA). The CIMBA series represents the largest
collection of MBCs arising in BRCA1 and BRCA2 mutation
carriers to date. In our series, the majority of MBC cases
(375 of 419, 89.5 %) were BRCA2 mutation carriers, a find-
ing which corroborates prior, smaller studies.
In this study, we conducted the first comparison of the
pathologic features of breast cancer arising in male and
female BRCA1/2 mutation carriers, taking advantage
of the previously collected pathology data from female
BRCA1/2 mutation carriers assembled by CIMBA [13].
We found that breast cancer in male BRCA2 mutation
carriers was of significantly higher stage and histologic
grade, and was more frequently ER+ and PR+, than breast
cancer in female BRCA2 mutation carriers. Advanced
stage disease at breast cancer diagnosis is more frequently
observed in men than in women [23]. In general, this is
thought to reflect diagnostic delay in a population un-
aware of its risk and (appropriately) not encouraged to
undergo routine breast cancer screening. Furthermore,
although breast cancer primaries in men tend to be
slightly smaller than those in women when they are
first diagnosed, they more often have locoregional me-
tastasis at presentation. Indeed, we found that male
BRCA2 mutation carriers presented more frequently
with lymph node involvement than breast cancer in female
mutation carriers.
It is known that MBC presents with lower histologic
grade tumours than FBC in the general population [11].
In contrast, in the present study, we showed that MBC
associated with BRCA2 mutations presents with higher
histologic grade than both breast cancer in female BRCA2
mutation carriers and MBC in the general population
from SEER.
We observed that the majority of BRCA2 MBCs are of
grades 2 and 3. However, grade 3 tumours were more
frequent among male BRCA2 mutation carriers diagnosed
at younger ages (younger than age 50 years) than among
those diagnosed at older ages, whereas grade 2 tumours
showed an inverse trend. Age-specific proportions of MBCs
stratified by grade show that grade 3 significantly decreased
with increasing age in male BRCA2 mutation carriers.
These results may indicate that young male BRCA2 muta-
tion carriers could be susceptible to more aggressive (i.e.,
high-grade) breast cancer. Differences in grade among male
breast carcinomas by age may be an indicator of a biologic
complexity in MBC, as suggested in FBC [24].
In a previous, single-country case series, MBCs associated
with BRCA2 mutations were found to be of higher grade
than non-BRCA2 MBC [16]. In the present study, we con-
firmed this association in a large, multicentre series and
showed that this association was age-specific. The identifi-
cation of a specific BRCA2-associated phenotype suggestive
of an aggressive behaviour might define a subset of MBC
patients (i.e., patients with high-grade breast tumours and
with young age at diagnosis) who may particularly benefit
from adjuvant chemotherapy [2, 25].
We also showed that high-grade breast tumours were
more likely to arise in male than in female BRCA2 muta-
tion carriers, indicating that BRCA2 mutations might be
associated with different breast cancer phenotypes in
men and in women. It has been suggested that high grade
is a surrogate for proliferation, and, although the evidence
is conflicting, this may add to the understanding of the
molecular differences of MBC and FBC.
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MBC is recognised as being primarily a hormone-
dependent malignancy, and, in general, MBC is described
as being more frequently ER+ and PR+ than FBC [10, 11,
23]. In the present study, we showed that BRCA2 MBCs
are more likely than BRCA2 FBCs to be ER+ and PR+, thus
suggesting that susceptibility to hereditary breast cancer
may be influenced by differences in hormonal background
between male and female BRCA2 mutation carriers.
Invasive lobular carcinomas are very rare in men, ac-
counting for only about 2 % of all MBCs [23, 26]. We
also found significantly fewer lobular carcinomas among
male than female BRCA2 mutation carriers. However, it
is worth noting that breast cancers in female BRCA2
mutation carriers frequently show a lobular morphology
[13], thus suggesting differences in the pathogenic mech-
anisms of male and female BRCA2 breast cancer.
The number of MBC cases with BRCA1 mutations in
our datasets was much smaller than the number of
BRCA2 mutation carriers, and our results in this subset
of patients should therefore be interpreted with caution.
We found that BRCA1 MBC cases were of significantly
higher stage, and more frequently ER+ and PR+, than
BRCA1 FBCs. Despite the small sample size, our results
suggest that hormone receptor pathways also are a driving
force in BRCA1 MBC. It is well known that most of the
breast tumours arising in female BRCA1 mutation carriers
tend to be ER− and PR−, with a small percentage being ER
+ [13, 27, 28]. Given that both ER− and ER+ BRCA1 breast
cancers seem to originate from a common luminal progeni-
tor cell population, it has been suggested that ER status of
breast cancer occurring in BRCA1 mutation carriers may
be under control of different molecular mechanisms [29].
The finding that MBCs associated with BRCA1 mutations
are frequently ER+ suggests that the hormonal milieu may
be a mechanism controlling ER status in BRCA1 tumours.
The different hormonal background between males and
females and the absence of hormone exposures related
to reproductive history in males as compared with FBC
may also influence biologic and molecular mechanisms
underlying the pathologic differences between MBC and
FBC. Following the findings in the present study, future
studies are warranted which focus on the comprehensive
somatic and molecular profiling of MBC and FBC in mu-
tation carriers. Such studies could provide new insights
into the complex nature of the origin and evolution of
MBC and FBC.
Interestingly, we found no statistically significant dif-
ferences in the pathologic characteristics between MBCs
in BRCA1/2 mutation carriers and those in the general
population, with the exception of histologic grade. Male
BRCA2 mutation carriers more frequently have grade 2/3
vs. grade 1 tumours, compared with the large, unselected
population of MBC cases from SEER. A similar trend also
was observed for BRCA1 mutation carriers. These findings
suggest that, although MBCs arising in male BRCA1/2
mutation carriers seem to be very similar to MBCs arising
in the general population, according to morphologic and
immunophenotypic features, they represent a subgroup
characterised by aggressive biology.
The importance of histologic grade as a prognostic
factor in breast cancer has been ascertained in FBC [30].
Recent data indicate that high-grade tumours are associated
with shorter disease-free survival and overall survival rates
in MBC patients [25]. Thus, on the basis of our results, we
can suggest that BRCA2 MBC may display an aggressive
phenotype and possibly a more unfavourable prognosis.
This is a question in need of additional survival data that
we are planning to collect within CIMBA.
In this study, tumour pathology data were collected
through several mechanisms, including medical records,
pathology reports and TMAs. Given the global distribution
of CIMBA study sites, central pathology review was not
feasible. Laboratory methods for tissue preparation, IHC,
biochemical assays, scoring systems and data interpretation
vary widely (Additional file 3), and misclassifications cannot
be excluded. Unfortunately, details of hormone receptor
scoring for all mutation carriers were not available to stand-
ardise definitions across centres. However, data collected by
CIMBA are more representative of typical assessment of
pathology conducted in routine practice, and the distribu-
tions of hormone receptors’ status across different study
centres and countries in CIMBA were generally consistent.
There was some variation in the distribution of some vari-
ables, including ER status, probably due to changing assay
thresholds and detection methods over time and from
country to country. Therefore, adjustments based on calen-
dar year of diagnosis and country of origin were included
for all analyses. Missing data for some variables, including
HER2 status, and the very small number of male BRCA1
mutation carriers in the study may have impacted the
statistical power to detect associations.
CIMBA collects data only on BRCA1 and BRCA2
mutation carriers. Therefore, to compare the tumour
characteristics of MBC from the general population,
we took advantage of the publicly available SEER data
[20]. Although the U.S. SEER program is the largest
source of epidemiologic information on the incidence
and survival rates of cancer, it includes data from a
single country, and this represents a limitation when
attempting to generalise our findings to what one would
expect in a collaborative international consortium. How-
ever, results from this study, based on a large, multicentre
series, replicated previous findings of much smaller studies
carried out in single populations [14–17], providing some
reassurance that our results were not biased by the differ-
ent selection of cases in SEER and in CIMBA. In addition,
SEER includes MBCs that were not screened for BRCA1
and BRCA2 mutations, and it can be expected that about
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10 % of those cases [3, 21, 22] may be due to BRCA1 or
BRCA2 mutations. In future studies, researchers should
aim to compare BRCA1/2 MBC cases with those known
not to have BRCA1/2mutations.
Conclusions
Analysing the largest series of BRCA1 and BRCA2 breast
cancers collected to date from both sexes, we have dem-
onstrated that breast tumours arising in BRCA1 and
BRCA2 mutation carriers display pathologic differences
between males and females. Thus, our results add to the
accumulating evidence that breast cancer may not be
the same disease in both genders [12] and suggest that
the heritable influence on breast cancer susceptibility
may be context-dependent, perhaps influenced by the
microenvironment (i.e., a different hormonal milieu in
males and females).
Moreover, we identified a specific BRCA2-associated
MBC phenotype characterised by higher histologic grade
compared with both BRCA2 FBC and MBC from a general
population. This raises the possibility that BRCA2 MBC
may be more aggressive than its sporadic counterpart.
Overall, our findings could lead to the eventual devel-
opment of clinical strategies appropriate for MBC man-
agement, and of gender-specific risk prediction models
that might guide more targeted screening and surveillance
programs for male mutation carriers.
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